Leveraging over 30 years of technical accumulation and project experience, JOINN Laboratories has built a standardized research system with high translational value covering multiple disease areas. Equipped with world-class experimental facilities and testing equipment, and under professional oversight by senior expert teams led by domestic and overseas PhD holders, we ensure all research data is accurate, compliant and traceable. Our core services include:
• In Vivo Disease Model Services
• Pharmacodynamic Evaluation Services
• Mechanism of Action Research Services
• IND Application Support Services
Drawing on 30+ years of model development experience, JOINN Laboratories has built hundreds of standardized, clinically relevant in vivo disease models covering ten disease systems.
Adopt standardized models closely recapitulating human T2DM pathological features; comprehensively assess the drug’s blood glucose and lipid regulatory effects, define effective dose ranges; ensure data is directly applicable for global IND submissions while controlling R&D cycle and costs.
Based on the client’s drug target and R&D requirements, we selected two classic T2DM models: db/db mice and ZDF rats. We established well-controlled blank and gradient dose groups to guarantee experimental rigor. We adopted core testing workflows including dynamic blood glucose monitoring and glucose clamp assays to comprehensively evaluate hypoglycemic efficacy. Under the full oversight of our GLP quality management system, the QA team supervised all procedures, with PhD-level experts overseeing experimental design and data interpretation and optimizing protocols in real time.
Utilize standardized models recapitulating human tumor immune microenvironments; comprehensively assess the drug’s capacity to inhibit tumor growth and metastasis; explore its regulatory effects on systemic immune cell populations; deliver study reports fully compliant with FDA, EMA and NMPA standards to enable direct use for global IND submissions while guaranteeing efficient project progression.
Based on the candidate’s mechanism of action (PD-1 immune checkpoint inhibition), we constructed MC38 colorectal cancer syngeneic transplantation models in C57BL/6 mice. This model retains the host’s intact immune system and accurately recapitulates human tumor immune microenvironments. We established blank control and gradient dose groups, utilized in vivo bioluminescence imaging systems to dynamically monitor tumor growth and metastasis, combined with flow cytometry for immune cell subset quantification and cytokine profiling to comprehensively assess tumor growth inhibition rates and immunomodulatory activity. PhD-level oncology pharmacology experts oversaw experimental design and data interpretation throughout the project, with dedicated QA teams providing full-cycle supervision to guarantee fully compliant workflows and accurate, traceable data.
Construct standardized botulinum toxin efficacy evaluation models utilizing globally accepted readouts; comprehensively assess the toxin’s efficacy strength, duration of action and safety; deliver study reports fully compliant with NMPA specifications; provide supplementary support including IND dossier compilation and regulatory inquiry responses to ensure smooth IND approval.
Drawing on our accumulated expertise in neuropharmacology and toxin pharmacodynamic assessment, we constructed botulinum toxin efficacy evaluation models using SD rats. We adopted internationally recognized core testing indicators including LD50 potency testing, DAS digit abduction scoring and CMAP compound muscle action potential electrophysiological detection to deliver comprehensive, precise quantification of toxin efficacy intensity and duration of action. All experimental procedures strictly adhere to GLP standards with fully standardized SOPs, operated by dedicated technical teams under full QA supervision to guarantee accurate, reproducible and traceable experimental data. We also assigned dedicated specialists to assist the client with IND dossier sorting and regulatory inquiry responses, optimizing the overall submission strategy.
